Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer

Inclusion Criteria:

Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate
For patients who have recurrent disease following surgery as first line therapy ("surgical failures")
PSA requirement is 0.2 ng/ml or above
For patients who have recurrent disease following radiation as first line therapy, the eligibility follows the "Phoenix criteria", that is, a rise of 2 ng/mL over the PSA nadir
Eastern Cooperative Oncology Group (ECOG) performance status =< 2
Granulocytes >= 1000/uL
Serum creatinine =< 2.0 mg/dl
Total serum calcium > 9.0 and < 10.5 mg/dl
Total bilirubin =< 2.0 mg/dl
Platelet count >=100,000/uL
Hemoglobin (Hgb) >= 9 g/dL
Total testosterone >= 50 ng/dL
Ability to understand and the willingness to sign a written informed consent document (either directly or via a legally authorized representative)

Exclusion Criteria:

Serious medical illness which would limit survival to less than 3 months
Active, uncontrolled bacterial, viral or fungal infection
Hemorrhagic disorder
Any radiographic evidence of metastatic disease including positive bone scan or computed tomography (CT) abdomen/pelvis
History of hypocalcemia or seizure disorder
Patients with known hypersensitivity to any of the components of cinacalcet (cinacalcet hydrochloride)